Jade Biosciences (JBIO) Liabilities and Shareholders Equity (2020 - 2026)

Jade Biosciences (JBIO) has 7 years of Liabilities and Shareholders Equity data on file, last reported at $319.4 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 312.0% year-over-year to $319.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.1 billion (up 210.39% YoY) and the FY2025 annual result came in at $349.8 million, up 380.48% from the prior year.
• Liabilities and Shareholders Equity eased to $319.4 million in Q1 2026, from $349.8 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $349.8 million in Q4 2025 to a low of $72.8 million in Q4 2024.
• A 5-year average of $159.4 million and a median of $140.9 million in 2023 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2024 — Liabilities and Shareholders Equity tumbled 42.87% — and 2025, when it soared 380.48%.
• Tracing JBIO's Liabilities and Shareholders Equity over 5 years: stood at $135.3 million in 2022, then dropped by 5.83% to $127.4 million in 2023, then slumped by 42.87% to $72.8 million in 2024, then surged by 380.48% to $349.8 million in 2025, then fell by 8.68% to $319.4 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $319.4 million (Q1 2026), $349.8 million (Q4 2025), and $202.4 million (Q3 2025), per Business Quant data.